dexisoproterenol

TNX-201 is a proprietary sublingual formulation of dexisoproterenol ((R)-isoproterenol), which is the more active enantiomer of the non-selective beta-adrenergic agonist isoproterenol. Developed by Tonix Pharmaceuticals, TNX-201 was designed to treat episodic tension-type headache (TTH) by leveraging the potential analgesic effects of beta-adrenergic receptor stimulation. The drug utilized a sublingual delivery technology intended for rapid absorption. However, in a 2015 Phase 2 clinical trial (TNX-201-001), the drug failed to demonstrate a statistically significant difference from placebo in achieving pain-free status at two hours post-dose. Following these results, Tonix Pharmaceuticals discontinued the development of TNX-201 for the treatment of tension-type headache.

Other names

(R)-isoproterenolL-isoproterenoldexisoprenaline